DRC Ebola Outbreak Spreads Across Borders; No Approved Vaccine for Bundibugyo Strain, Asymmetric R&D Exposes Response Gaps

Kenya confirmed its first imported cross-border case of Bundibugyo virus disease on October 6; the patient had died at a Nairobi hospital on October 5. According to Al Jazeera, the Kenyan citizen had been residing in the Democratic Republic of the Congo (DRC), where they developed symptoms and sought medical care multiple times, then traveled by land to Kampala, Uganda, before flying to Nairobi on October 3. Kenyan authorities have identified 28 contacts, including family members and healthcare workers, while the World Health Organization has simultaneously launched tracking of passengers and crew on the flight involved.

This imported case exposes the risk of the outbreak spreading beyond the DRC. The WHO's October 8 briefing shows that the outbreak has spread within the DRC to 7 provinces and 64 health zones, with North Kivu's Alimbongo health zone reporting cases for the first time; as of October 6, 4 confirmed cases and 2 deaths had been recorded. Ituri Province still has the highest cumulative case count in the country, while North Kivu's share of new confirmed cases nationwide continues to rise. As of October 6, the WHO had cumulatively recorded 8,728 confirmed Ebola cases in the DRC, 4,205 deaths, 2,269 recoveries, with a case fatality rate of 48.2%.

The most fundamental bottleneck is the absence of vaccines and specific treatments. The WHO has clearly stated that no approved vaccine or specific therapeutic exists for Bundibugyo virus disease; early identification, supportive care, and infection control remain the core of the response. This stands in sharp contrast to the previous outbreak in the DRC from 2018 to 2020, caused by the Zaire strain of Ebola virus — that outbreak ultimately caused nearly 2,300 deaths and received vaccine resources targeting the Zaire strain during the response. Yet this Bundibugyo outbreak has caused over 4,200 deaths, with still no approved vaccine or specific therapy targeting the strain, leaving a clear gap in the R&D pipeline — the available materials do not indicate whether the international community's vaccine R&D commitments for the strain are adequate.

Treatment capacity is also approaching its limits. Médecins Sans Frontières (MSF) reported on October 5 that recent new confirmed cases in North Kivu now account for nearly 40% of the national figure; as of September 28, 34% of confirmed Ebola patients were being treated at non-specialized health facilities, with severe bed shortages at dedicated treatment centers, forcing some patients to be referred to medical institutions not equipped for Ebola management. MSF's Ebola Treatment Center coordinator in Butembo, Stephanie Hoffmann, said bluntly: "Treatment capacity has been approaching its limits for weeks. Because there are not enough beds, we sometimes have to transfer confirmed patients elsewhere, which poses a significant risk to the wider community. In addition, the standard of care at some peripheral medical facilities may not meet Ebola treatment requirements, which is very worrying."

Contact tracing has also failed to meet targets. WHO data shows that as of October 4, response teams had tracked 23,741 of the 29,535 identified contacts, a follow-up rate of 80.4%, below the response target of at least 85%. Africa CDC Director-General Jean Kaseya warned: "To get this outbreak under control, we need to know where every contact is, trace them, and quickly identify any symptomatic individuals before they transmit the virus to their families, community, or across borders. Only by cutting off the last transmission chain can we bring the outbreak under control."

Community-level resistance is exacerbating the difficulty. According to Al Jazeera, Watoto Radio founder Daniel Makasi Levergénois said that insecurity and misinformation are undermining the outbreak response in Beni and Butembo, with some residents resistant to response teams. Beni community leader Alberto Lusenge warned that Ituri Province's failure to interrupt transmission early on, combined with attacks on response personnel in Beni and Butembo, have deepened public anxiety; without stronger community cooperation, North Kivu could become a new epicenter of the outbreak. The deeper historical causes of community distrust have not been adequately explained in the available materials.

The fragility of cross-border coordination was starkly demonstrated in the Kenyan case. The patient was not detected or intercepted during multiple medical visits within the DRC and cross-border movement, exposing structural shortcomings in the East African region's cross-border public health surveillance network. The Kampala-to-Nairobi air route is one of the major corridors for human movement in East Africa, and the absence of airport screening, cross-border information sharing, and joint contact tracing mechanisms allowed a highly dangerous imported case to complete the entire journey. Specific measures from the Ugandan side and final contact coverage rates remain incomplete in the available materials.

On October 8, preliminary laboratory test results for a suspected case in Kenya's Wajir County came back negative, temporarily easing external concerns about a possible second case, but surveillance is ongoing.

Africa CDC has called for a community-centered response strategy, including active case finding, systematic contact tracing, daily follow-up of exposed individuals, and sustained engagement with communities. Facing the reality of no approved vaccine, saturated treatment capacity, and substandard contact tracing, whether this outbreak can be contained depends on substantial improvements in cross-border coordination and the international community filling in the R&D and response gaps — and the latter remains a blank in the available materials.